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Introduction. The prevalence of breakthrough pain, affects the quality of life of patients. Onset is unpredictable in 78% of all cases,
quick start (up to 5′) and short duration (<45′).
Objective. Evaluate the effectiveness of three drugs (Abstral, Effentora and PecFent) in breakthrough cancer pain: a randomized
observational study of 30 patients, 3 month follow up.
Materials and methods. We analyzed the parameters that assess the effectiveness and comfort of analgesic treatment, through
a randomized observational study. The inclusion of patients was conducted in consultation during treatment of an episode
of breakthrough pain; we included patients that take opioids for basal pain, and a life expectancy of more than six months.
Once the patient was included in the study we conducted a ﬁrst interview, they were randomly assigned to use the drug type,
epidemiological surveys, KARNOFSKY index, and adjunctive treatments graduation pain intensity (VAS). On subsequent visits
(4) data were collected: Time effect and/or maximum effect, number of episodes, VAS pain on movement and/or the degree of
comfort rest and drug use.
Results. Median age of (68.9), n: 30 (12 women and 18 men). Drug descending order: (1) Comfort: Abstral–EFFENTORA–PecFent; (2)
Time effectiveness: EFFENTORA–Abstral–PecFent; (3) Major adverse effects: EFFENTORA–PecFent–Abstral.
Conclusions. It should be considered as routine clinical practice, these drugs are indicate “prophylactically” in patients with bone
disease requiring mobilization during treatment and in the head-neck pathologies during meals. No signiﬁcant differences in
toxicity. Keep in mind the comfort level indication. Properly adjust the base analgesia, signiﬁcantly decreases the number of
processes irruptive.
http://dx.doi.org/10.1016/j.rpor.2013.03.181
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Introduction. Breast radiodermatitis not always appear uniformly distributed throughout the breast. Throughout the treatment,
it is common to see more affection in some areas than in others.
Objective. Get a working method to help us improve nursing care in breast carcinoma radiodermatitis.
Materials and methods. An observational, longitudinal and prospective study in 2012 on 35 women diagnosed with breast cancer
radiotherapy after conservative surgery. To evaluate the degree of radiation dermatitis was used scale RTOG/EORTC. To locate
where the ﬁrst signs or where further intensiﬁes the degree of radiation dermatitis, was performed in addition to the general
evaluation of the breast, an assessment by area. There are differentiated localization in 9 areas: axilla, submammary fold, nipple,
areola, supraclavicular and each of the quadrants of the breast. The assessment of the signs of breast radiodermatitis was
conducted in weekly from the ﬁrst to the last and one month after stopping treatment.
Results. During the weekly review, in 24 of the 35 women appeared radiodermatitis degrees higher when this assessment was
carried out in speciﬁc areas when performed in the general assessment of the breast. Performing radiodermatitis averages with
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